GERON CORP
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $GERN in the last 7 days.
No SEC Form 4 filings for $GERN in the last 30 days.
See all $GERN insider activity →Analysts commented on Geron (GERN) and Fair Isaac (FICO). H.C. Wainwright maintained a Hold rating on GERN with a $1.50 target, while Wells Fargo reiterated a Buy on FICO with a $1350 target. GERN has a Strong Buy consensus and 233.1% upside, FICO has a Moderate Buy consensus and 56.3% upside.
Geron (GERN) anticipates RYTELO revenue near the high end of 2026 guidance, with over one-third of patients now in earlier treatment lines. The company plans to update its European strategy by year-end, considering partnerships or targeted commercial activities. Geron has $320M in cash and is evaluating business development opportunities. RYTELO is approved for certain myelodysplastic syndromes.
Geron Corp. (GERN) reported Q4 2025 revenue of $48M, missing estimates, with an EPS loss of $0.05. RYTELO sales grew 9% QoQ to $48M. The stock fell 10% premarket. Operating costs were $254.7M, with restructuring charges of $17M. Geron projects 2026 RYTELO revenue of $220M-$240M.
Recent GERN coverage spans earnings, financial news and market movers.
Analyst rating reiteration with modest upside target.
Guidance uplift may boost near‑term price as investors re‑price growth expectations.
Earnings miss drives immediate sell pressure; short‑term downside risk.
The guidance provides a concrete near-term revenue anchor for RYTELO, likely supporting momentum but keeping the stock highly sensitive to launch execution and cash needs.
Fresh guidance and updated results reframe the valuation debate around RYTELO revenue growth and loss narrowing, with financing risk still highlighted.
AlphAI scores every news story that mentions GERN with an AI model for sentiment and relevance, and aggregates insider trades from GERON CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts commented on Geron (GERN) and Fair Isaac (FICO). H.C. Wainwright maintained a Hold rating on GERN with a $1.50 target, while Wells Fargo reiterated a Buy on FICO with a $1350 target. GERN has a Strong Buy consensus and 233.1% upside, FICO has a Moderate Buy consensus and 56.3% upside.
1 min readGeron (GERN) anticipates RYTELO revenue near the high end of 2026 guidance, with over one-third of patients now in earlier treatment lines. The company plans to update its European strategy by year-end, considering partnerships or targeted commercial activities. Geron has $320M in cash and is evaluating business development opportunities. RYTELO is approved for certain myelodysplastic syndromes.
2 min readGeron Corp. (GERN) reported Q4 2025 revenue of $48M, missing estimates, with an EPS loss of $0.05. RYTELO sales grew 9% QoQ to $48M. The stock fell 10% premarket. Operating costs were $254.7M, with restructuring charges of $17M. Geron projects 2026 RYTELO revenue of $220M-$240M.
2 min readGeron Corp (GERN) shares rose 14.7% after the company issued its first full-year 2026 RYTELO revenue guidance of $220 million to $240 million. Geron reported Q2 revenue of $57.48 million and a net loss of $16.68 million. For the first half, revenue was $109.32 million with a $20.32 million net loss, alongside discussion of analyst price targets.
6 min readSimply Wall St reports Geron (GERN) issued 2026 earnings guidance tied to RYTELO net product revenue and released Q2 and half-year 2026 results on Aug 5. The article cites a $1.48 share price, guidance and updated revenue and net loss figures, and a “fair value” estimate of $3.40 versus $1.48, with a consensus price target of $3.625.
7 min readGeron (NASDAQ:GERN) said about 8,000 U.S. patients may be eligible for RYTELO in second-line, lower-risk MDS. The company guided 2026 RYTELO net product revenue to the mid-to-high end of $220 million to $240 million and expects operating expenses of $230 million to $240 million. Q2 gross-to-net deductions rose to 20.7%.
6 min readGERON CORP (GERN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights August 5, 2026 Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product rev
6 min readBiotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.
3 min readGeron Corporation reported Q2 2026 results on its RYTELO business, citing 17% year-over-year net revenue growth and 24% net revenue growth in the first half of 2026 with total operating expenses down 4%. Full-year 2026 RYTELO net revenue guidance is $220M to $240M. Cash was $327M. Operating expenses guidance is $230M to $240M.
4 min readThe article lists 10 “fastest growing” tech penny stocks under $5, using a Finviz screen for over 50% compounded annual revenue growth in 3 years and recent catalysts. It highlights PowerFleet (NASDAQ:AIOT) launching SafeGuard, reporting up to 83% on-road risk reduction, and approving a $30M repurchase. It also covers Geron (NASDAQ:GERN) granting 690,000 options at $1.23.
7 min read
